

PRODUCT INFORMATION



N-desethyl Sunitinib

Item No. 22292

CAS Registry No.: 356068-97-8

Formal Name: N-[2-(ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide

Synonym: SU 12662

MF: $C_{20}H_{23}FN_4O_2$

FW: 370.4


Purity: $\geq 95\%$

UV/Vis.: λ_{max} : 268, 429 nm

Supplied as: A crystalline solid

Storage: $-20^{\circ}C$

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

N-desethyl Sunitinib is supplied as a crystalline solid. A stock solution may be made by dissolving the N-desethyl sunitinib in the solvent of choice, which should be purged with an inert gas. N-desethyl Sunitinib is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of N-desethyl sunitinib in these solvents is approximately 20 mg/ml. N-desethyl Sunitinib is slightly soluble in ethanol.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of N-desethyl sunitinib can be prepared by directly dissolving the crystalline solid in aqueous buffers. N-desethyl sunitinib is slightly soluble in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

N-desethyl Sunitinib is an active metabolite of sunitinib (Item No. 13159), a small molecule, multi-targeted receptor tyrosine kinase inhibitor.^{1,2} N-desethyl Sunitinib is formed when sunitinib undergoes N-de-ethylation by the cytochrome P450 (CYP) isomer CYP3A4.² N-desethyl Sunitinib is pharmacologically active having similar inhibitory activity to sunitinib.

References

1. O'Farrell, A.M., Abrams, T.J., Yuen, H.A., *et al.* SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. *Blood* **101**(9), 3597-3605 (2003).
2. Yu, H., Steeghs, N., Kloth, J.S.L., *et al.* Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. *Br. J. Clin. Pharmacol.* **79**(5), 809-819(2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/02/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM